Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2023
Date of Report: May 9, 2023
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
This filing serves as a cover document for a press release dated May 9, 2023 (Exhibit 99.1). The text provided contains only the cover page and signature block; the content of the press release is not included in the source text.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not provide details regarding material changes versus prior periods. The specific nature of the announcement contained in the referenced press release is not described in the cover document.
Guidance, Outlook, and Risks
No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided text. The document solely confirms the submission of a press release by Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) referenced in this filing to understand the specific corporate event or announcement.
- Confirm if the press release contains material non-public information regarding clinical trials, partnerships, or financial results.
- Review the company's most recent Form 20-F for baseline financial data, as this 6-K does not include financial statements.